Edgewell Personal Care

EPC · NYSE

$28.22+$0.42 (+1.51%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $27.80

EPC analyst rating

BuyConsensus of 6 analysts over the last 12 months. 50% rate it a buy.

Strong buy0
Buy3
Hold3
Underperform0
Sell0

12-month price target · 7 analysts

Average $32.81 (+16.3% upside)

Low: $29.29
Now: $28.22
High: $36.75

Upgrades and downgrades

The latest rating actions, newest first

EPC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 5, 2026	Maintains	Overweight	$32.00 → $30.00	57%
Barclays	Aug 7, 2026	Maintains	Equal-Weight	$28.00 → $29.00	62%
UBS	Aug 6, 2026	Maintains	Neutral	$29.00 → $32.00	62%
RBC Capital	Aug 6, 2026	Maintains	Outperform	$26.00 → $35.00	45%
Barclays	Jul 21, 2026	Maintains	Equal-Weight	$21.00 → $28.00	62%
UBS	Jul 16, 2026	Maintains	Neutral	$23.00 → $29.00	62%
Wells Fargo	Jul 8, 2026	Maintains	Overweight	$24.00 → $30.00	57%
Canaccord Genuity	Jul 7, 2026	Maintains	Buy	$32.00 → $34.00	42%
UBS	May 8, 2026	Maintains	Neutral	$21.00 → $23.00	62%
Barclays	Feb 10, 2026	Maintains	Equal-Weight	$19.00 → $21.00	62%

The case for and against

Updated Oct 22, 2025

Bull case

Edgewell Personal Care Co has demonstrated a positive trend in net sales, with a 3% increase in the second fiscal quarter, attributed to both price and volume gains. Although operating margins are projected to contract, gross margins are expected to expand by 10 basis points, reflecting the company's strategic investments and management of incremental tariffs. Furthermore, the company maintains a robust EBITDA forecast of $334 million, underscoring its operational efficiency and overall financial health, despite some downward revisions in broader sales and earnings expectations.

Bear case

Edgewell Personal Care Co has experienced a decline in net sales of 4% in North America, primarily driven by volume reductions in key segments such as Wet Shave, Feminine Care, and Sun Care. Additionally, the company is facing increased tariff costs that are expected to further impact profitability. The need for ongoing reinvestment to drive revenue growth has resulted in constrained earnings before interest and taxes (EBIT) and free cash flow (FCF) growth, compounded by a relatively high cost of capital and low terminal growth rate assumptions.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.